Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial

Keyphrases

• Phase II Trial 100%
• Disease-modifying Therapy 100%
• Alemtuzumab 100%
• Disability 18%
• Relapse Rate 12%
• Disease Activity 6%
• Hazard Ratio 6%
• Early Identification 6%
• Safety Assessment 6%
• Adverse Effects 6%
• Previously Untreated Patients 6%
• One Dose 6%
• Rate Ratio 6%
• Treatment Refractory 6%
• Relapse-free 6%
• Risk Management Strategies 6%
• Immune Thrombocytopenia 6%
• Interferon-β (IFN-β) 6%
• Anti-CD52 Monoclonal Antibody 6%
• Voice User Interface 6%
• Infusion Reaction 6%
• Relapse Time 6%
• Thyroid Disorders 6%
• Co-primary Endpoints 6%

Pharmacology, Toxicology and Pharmaceutical Science

• Multiple Sclerosis 100%
• Alemtuzumab 100%
• Diseases 100%
• Recurrence Risk 11%
• Adverse Event 5%
• Infection 5%
• Safety Assessment 5%
• Disease Activity 5%
• Idiopathic Thrombocytopenic Purpura 5%
• Thyroid Disease 5%
• Beta Interferon 5%
• Glatiramer 5%

Immunology and Microbiology

• Interferon Beta 1a 52%
• Relapsing Remitting Multiple Sclerosis 17%
• Interactive Voice Response System 5%